MXPA05010064A - Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos. - Google Patents

Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.

Info

Publication number
MXPA05010064A
MXPA05010064A MXPA05010064A MXPA05010064A MXPA05010064A MX PA05010064 A MXPA05010064 A MX PA05010064A MX PA05010064 A MXPA05010064 A MX PA05010064A MX PA05010064 A MXPA05010064 A MX PA05010064A MX PA05010064 A MXPA05010064 A MX PA05010064A
Authority
MX
Mexico
Prior art keywords
compound
compound according
further characterized
methyl
mmol
Prior art date
Application number
MXPA05010064A
Other languages
English (en)
Spanish (es)
Inventor
Madeleine M Joullie
Original Assignee
Madeleine M Joullie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madeleine M Joullie filed Critical Madeleine M Joullie
Publication of MXPA05010064A publication Critical patent/MXPA05010064A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05010064A 2003-03-21 2004-03-19 Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos. MXPA05010064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45696703P 2003-03-21 2003-03-21
PCT/US2004/008275 WO2004084812A2 (en) 2003-03-21 2004-03-19 Tamandarin analogs and fragments thereof and methods of making and using

Publications (1)

Publication Number Publication Date
MXPA05010064A true MXPA05010064A (es) 2006-05-17

Family

ID=33098178

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010064A MXPA05010064A (es) 2003-03-21 2004-03-19 Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.

Country Status (8)

Country Link
US (1) US8030279B2 (https=)
EP (1) EP1613338A4 (https=)
JP (1) JP2006523214A (https=)
CN (1) CN1819837A (https=)
AU (1) AU2004224418A1 (https=)
CA (1) CA2519234A1 (https=)
MX (1) MXPA05010064A (https=)
WO (1) WO2004084812A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1423564A (zh) * 1999-11-15 2003-06-11 法马马有限公司 癌症的aplidine治疗
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ES2272462T3 (es) * 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
EP1942193A4 (en) 2005-08-25 2010-10-27 Ube Industries METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE (S OR R) -AMINOIC ACID OR AN OPTICALLY ACTIVE (S OR R) -α-AMINO-ACID ESTER
CN101389347B (zh) 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
JP5396016B2 (ja) * 2007-03-26 2014-01-22 学校法人青山学院 化合物又はその薬理上許容される塩若しくはエステル誘導体及び制癌剤
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
CN104003908B (zh) * 2014-01-17 2016-08-17 宁波北仑大港科技创新服务中心 一种保护羟基的丝氨酸的制备方法
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
CA3169544A1 (en) 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
WO2021175826A1 (en) 2020-03-02 2021-09-10 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
US12168640B2 (en) 2021-11-16 2024-12-17 ProDeg, LLC USP9X inhibitors
EP4433462A4 (en) * 2021-11-16 2025-07-16 Prodeg Llc USP9X INHIBITORS
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
DE69735583T2 (de) 1996-10-24 2007-04-05 The Board Of Trustees Of The University Of Illinois, Urbana Semisynthetisches verfahren zur herstellung von didemninanalogen
PT956033E (pt) 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ES2272462T3 (es) * 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
SE523235C2 (sv) * 2003-02-21 2004-04-06 Water Treat Construction I Mot Metod och anordning för att avskilja miljöfarliga ämnen ur en förorenad massa

Also Published As

Publication number Publication date
US20070149446A1 (en) 2007-06-28
AU2004224418A1 (en) 2004-10-07
EP1613338A2 (en) 2006-01-11
WO2004084812A3 (en) 2005-10-06
CN1819837A (zh) 2006-08-16
CA2519234A1 (en) 2004-10-07
EP1613338A4 (en) 2009-06-24
JP2006523214A (ja) 2006-10-12
US8030279B2 (en) 2011-10-04
WO2004084812A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
MXPA05010064A (es) Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.
EP1276491B1 (en) Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) Didemnin analogs and fragments and methods of making and using them
KR100866056B1 (ko) 아플리딘 및 신규의 항종양성 유도체의 합성 방법, 및 그제조 및 이용 방법
CA2852860A1 (en) Cytotoxic peptides and antibody drug conjugates thereof
CA2602070A1 (en) Cyclic nonapeptide amides
US6482921B1 (en) Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
RU2299887C2 (ru) Способы синтеза аплидина и новых противоопухолевых производных, способы их промышленного получения и применения
AU2006252266A1 (en) Tamandarin and didemnin analogs and methods of making and using them
AU2001267698B2 (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
AU2001267698A1 (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them